|Classification and external resources|
Pseudobulbar affect (PBA), emotional lability, labile affect, or emotional incontinence is a type of affect characterized by involuntary crying or uncontrollable episodes of crying and/or laughing, or other emotional displays. PBA occurs secondary to a neurologic disorder or brain injury. Patients may find themselves crying uncontrollably at something that is only moderately sad, being unable to stop themselves for several minutes. Episodes may also be mood-incongruent: a patient might laugh uncontrollably when angry or frustrated, for example.
- 1 Terminology
- 2 Signs and symptoms
- 3 Causes
- 4 Treatment
- 5 Epidemiology
- 6 History
- 7 See also
- 8 References
- 9 External links
Historically, there have been a variety of terms used for the disorder, including pseudobulbar affect, pathological laughter and crying, emotional lability, emotionalism, emotional dysregulation, or more recently, involuntary emotional expression disorder. The term pseudobulbar (pseudo- + bulbar) came from the idea that the symptoms seemed similar to those caused by a bulbar lesion (that is, a lesion in the medulla oblongata).
Terms such as forced crying, involuntary crying, pathological emotionality, and emotional incontinence have also been used, although less frequently.
Signs and symptoms
The cardinal feature of the disorder is a pathologically lowered threshold for exhibiting the behavioral response of laughter, crying, or both. An affected individual exhibits episodes of laughter and/or crying without an apparent motivating stimulus or in response to stimuli that would not have elicited such an emotional response before the onset of their underlying neurologic disorder. In some patients, the emotional response is exaggerated in intensity but is provoked by a stimulus with an emotional valence congruent with the character of the emotional display. For example, a sad stimulus provokes a pathologically exaggerated weeping response instead of a sigh, which the patient normally would have exhibited in that particular instance.
However, in some other patients, the character of the emotional display can be incongruent with, and even contradictory to, the emotional valence of the provoking stimulus or may be incited by a stimulus with no clear valence. For example, a patient may laugh in response to sad news or cry in response to stimuli with no emotional undertone, or, once provoked, the episodes may switch from laughing to crying or vice versa.
The symptoms of PBA can be severe, with persistent and unremitting episodes. Characteristics include:
- The onset can be sudden and unpredictable, and has been described by some patients as coming on like a seizure;
- The outbursts have a typical duration of a few seconds to several minutes; and,
- The outbursts may happen several times a day.
Many people with neurologic disorders exhibit uncontrollable episodes of laughing, crying, or both that are either exaggerated or contradictory to the context in which they occur. Where patients have significant cognitive deficits (e.g., Alzheimer's) it can be unclear whether it is true PBA as opposed to a grosser form of emotional dysregulation, but patients with intact cognition often report the symptom as disturbing. Patients report that their episodes are at best only partially amenable to voluntary control, and unless they experience a severe change of mental status, they often have insight into their problem and judge their emotional display as inappropriate and out of character. The clinical effect of PBA can be severe, with unremitting and persistent symptoms that can be disabling to patients, and may significantly affect quality of life for caregivers.
While not as profoundly disabling as the physical symptoms of these diseases, PBA can significantly influence individuals' social functioning and their relationships with others. Such sudden, frequent, extreme, uncontrollable emotional outbursts may lead to social withdrawal and interfere with activities of daily living, social and professional pursuits, and reduce overall healthcare. For example, patients with ALS and MS are often cognitively normal. However, the appearance of uncontrollable emotions is commonly associated with many additional neurological disorders such as attention deficit/hyperactivity disorder, Parkinson's disease, cerebral palsy, autism, epilepsy, and migraines. This may lead to severe embarrassment and avoidance of social interactions for the patient, which in turn impairs their coping mechanisms and their careers.
PBA may often be misdiagnosed as clinical depression; however, many clear distinctions exist.
In depression and grief syndromes, crying is typically a sign of sadness, whereas the pathological displays of crying which occur in PBA are often in contrast to the underlying mood, or greatly in excess of the mood or eliciting stimulus. In addition, a key to differentiating depression from PBA is duration: PBA episodes are sudden, occurring in a brief episodic manner, while crying in depression is a more sustained presentation and closely relates to the underlying mood state. The level of control that one has over the crying episodes in PBA is minimal or nonexistent, whereas for those suffering from depression, the emotional expression (typically crying) can be modulated by the situation. Similarly, the trigger for episodes of crying in patients with PBA may be nonspecific, minimal or inappropriate to the situation, but in depression the stimulus is specific to the mood-related condition. These differences are outlined in the adjacent Table.
In some cases, depressed mood and PBA may co-exist. In fact, depression is one of the most common emotional changes in patients with neurodegenerative disease or post-stroke sequelae. As a result, it is often comorbid with PBA. Comorbidity implies that depression is distinct from PBA and is not necessary for, nor does it exclude, a diagnosis of PBA.
The specific pathophysiology involved in this frequently debilitating condition is still under investigation; the primary pathogenic mechanisms of PBA remain controversial. One hypothesis, established by early researchers such as Wilson and Oppenheim, placed emphasis on the role of the corticobulbar pathways in modulating emotional expression in a top-down model, and theorized that PBA occurs when bilateral lesions in the descending corticobulbar tract cause failure of voluntary control of emotion, which leads to the disinhibition, or release, of laughing/crying centers in the brainstem. Other theories implicate the prefrontal cortex.
Pseudobulbar affect is a condition that occurs secondary to neurological disease or brain injury, and is thought to result from disruptions of neural networks that control the generation and regulation of motor output of emotions. PBA is most commonly observed in people with neurologic injuries such as traumatic brain injury (TBI) and stroke, and neurologic diseases such as dementias including Alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Lyme disease, PANDAS in children and adults, and Parkinson's disease (PD). It has been reported as a symptom of hyperthyrodism, Graves' Disease, or hypothyroidism in combination with depression.
PBA has also been observed in association with a variety of other brain disorders, including brain tumors, Wilson's disease, syphilitic pseudobulbar palsy, and various encephalitides. Rarer conditions associated with PBA include gelastic epilepsy, dacrystic epilepsy, central pontine myelinolysis, olivopontinocerebellar atrophy, lipid storage diseases, chemical exposure (e.g., nitrous oxide and insecticides), fou rire prodromique, and Angelman syndrome.
It is hypothesized that these primary neurologic injuries and diseases affect chemical signaling in the brain, which in turn disrupts the neurologic pathways that control emotional expression.
PBA is one of the most frequently reported post-stroke behavioral syndromes, with a range of reported prevalence rates from 28% to 52%. The higher prevalence rates tend to be reported in stroke patients who are older and/or who have a history of prior stroke. The relationship between post-stroke depression and PBA is complicated, because the depressive syndrome also occurs with high frequency in stroke survivors. Post-stroke patients with PBA are more depressed than poststroke patients without PBA, and the presence of a depressive syndrome may exacerbate the weeping side of PBA symptoms.
Recent studies suggest that approximately 10% of patients with multiple sclerosis (MS) will experience at least one episode of emotional lability. PBA is generally associated with later stages of the disease (chronic progressive phase). PBA in MS patients is associated with more severe intellectual deterioration, physical disability, and neurological disability.
Amyotrophic lateral sclerosis
A study designed specifically to survey for prevalence found that 49% of patients with amyotrophic lateral sclerosis (ALS) also had PBA. PBA does not appear to be associated with duration of ALS. It is a symptom of ALS that many patients are unaware of and do not receive information about from their physician.
Traumatic brain injury
One study of 301 consecutive cases in a clinic setting reported a 5% prevalence. PBA occurred in patients with more severe head injury, and coincided with other neurological features suggestive of pseudobulbar palsy.
The Brain Injury Association of America (BIAA) indicates that approximately 80% of survey respondents experience symptoms of PBA. Results from a recent investigation estimate the prevalence of PBA associated with traumatic brain injury to exceed more than 55% of survivors.
Education of patients, families, and caregivers is an important component of the appropriate treatment of PBA. Crying associated with PBA may be incorrectly interpreted as depression; laughter may be embarrassing. It is therefore critical for families and caregivers to recognize the pathological nature of PBA and the reassurance that this is an involuntary syndrome that is manageable. Traditionally, antidepressants such as sertraline, fluoxetine,citalopram, nortriptyline and amitriptyline have been prescribed with some efficacy.
Dextromethorphan hydrobromide is a generic drug that affects the signals in the brain that trigger the cough reflex. It is generally used as a cough suppressant, although it can sometimes be used, medicinally, as a pain reliever, and is also used as a recreational drug. "Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist."
Quinidine sulfate affects the way the heart beats, and is generally used in people with certain heart rhythm disorders. It is also used to treat malaria. Quinidine sulfate, as a metabolic inhibitor, "increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan," enabling therapeutic dextromethorphan concentrations.
Nuedexta is a patented combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010. In December 2007, clinical study information for Nuedexta was first submitted to ClinicalTrials.gov, (a Web-based resource maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH)). Sponsored by Avanir Pharmaceuticals, (with brief title, Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS), the study was assigned NCT Number NCT00573443. Final updates and verifications occurred in June 2013 on the ClinicalTrials.gov site.
For this multicenter study, the "Objectives...[were] to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 [Dextromethorphan/quinidine combination]...when compared to placebo." The conditions and results of that study are as follows:
At one study site, a total of 326 participants received one of three dose options. "METHODS: In a 12-week randomized, double-blind trial, ALS and MS patients with clinically significant PBA" were given a twice-daily dose of one of the following:
- placebo (N=109)
- dextromethorphan hydrobromide 30 mg/quinidine sulfate 10 mg (N=110)
- Nuedexta – dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg (N=107)
283 patients (86.8%) completed the study. The number of PBA episodes (laughing and crying) were 47% and 49% lower (based on the trial's outcome measures), respectively, for the drug-combination options than for the placebo. The "mean CNS-LS scores" decreased by 8.2 points for both drug-combination options, vs a decrease of 5.7 points for the placebo. Overall, the trial showed a statistically significant benefit from taking a combination of Dextromethorphan and quinidine, with both dosages being safe and well tolerated. For a secondary objective measuring a participant's "perceived health status...measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health," the higher dosage showed improvement, especially on measures of social functioning and mental health.
Other studies have confirmed the results of NCT00573443, but, "The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown."
Nuedexta is marketed by Avanir Pharmaceuticals. Founded in 1988, "Avanir Pharmaceuticals is a biopharmaceutical company engaged in acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders." In December 2014, Avanir announced a definitive deal with Japanese pharmaceutical giant, Otsuka Holdings, in which Otsuka would acquire Avanir for $3.54 billion.
While AVP-923 (Nuedexta) was tested and approved for treatment of PBA, "Avanir is also studying Nuedexta as a treatment for diabetic nerve pain, agitation in patients with Alzheimer's disease, central nerve pain in multiple sclerosis, and levodopa-induced dyskinesia in Parkinson's disease."
Avanir, and some of its collaborative partners, utilizes a drug development path whereby drug manufacturers begin with "known drug compound[s]," (an "approved drug, advanced clinical candidate or previously studied compound"), which are "improved with deuterium substitution," creating "deuterated analogs of approved drugs" which should result in "faster advancement into clinical development" with the "potential for [an] expedited clinical pathway."
AVP-786 is another developmental drug for Avanir, and is similar to AVP-923, but "contains quinidine at a lower dosage than that used in Nuedexta." The "fast-track" development program was successful for this drug:
"Following interactions with the FDA, an agreement was reached for a faster development path for Avanir's AVP-786...which contains deuterium-modified dextromethorphan and quinidine, [and] is being developed for the treatment of neurologic and psychiatric disorders. Under the agreement with the FDA, Avanir will be allowed to use the data generated on Nuedexta (AVP-923) to support the IND application as well as regulatory filings for AVP-786 in the US. This will not only help fasten [sic] the development process for AVP-786, it will also lower development-related costs."
Avanir sometimes collaborates with Concert Pharmaceuticals, Inc., and AVP-786 is a current "partnered drug," which Concert describes as "a combination of deuterium-substituted dextromethorphan and an ultra-low dose of quinidine...for the treatment of agitation in Alzheimer’s patients, schizophrenia, and as an adjunctive treatment of major depressive disorder (MDD)."
In addition, Avanir believes its drugs can be used to treat neuropathic pain, treatment-resistant depression, migraines, dyskinesia in patients suffering from Parkinson's disease, and adult autism. AVP-923 and AVP-786 are in clinical trials for "the treatment of neurologic and psychiatric disorders, including pain, behavioral disorders, mood disorders, and movement disorders."
Clinical Trials for AVP-786 and AVP-923
- Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition, NCT02534038, Not yet open for recruitment (Aug. 2015–; verified Aug. 2015). Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02534038
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia, NCT02477670, Currently recruiting (June 2015–; verified Dec. 2015), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02477670?term=avanir&rank=3
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type, NCT02446132, Currently recruiting (May 2015–; verified Dec. 2015), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02446132
- Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type, NCT02442778, Currently recruiting (May 2015–; verified Dec. 2015), Sponsor: Avanir Pharm. https://www.clinicaltrials.gov/ct2/show/NCT02442778
- Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type, NCT02442765, Currently recruiting (May 2015–; verified Dec. 2015), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02442765?term=avanir&rank=6
- Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment, NCT02153502, Currently recruiting (May 2014–; verified Jan. 2015), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02153502?term=avanir&rank=2
- Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA), NCT02496039, Currently recruiting (July 2015–; verified Dec. 2015), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02496039?term=AVP-923&rank=15
- Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine, NCT02176018, Currently recruiting (2014–; verified Jan. 2016), Sponsor: Cady, Roger, M.D., (Collaborator: Avanir Pharm.). https://clinicaltrials.gov/ct2/show/NCT02176018?term=AVP-923&rank=14
- Nuedexta in Treatment-Resistant Major Depression, NCT01882829, Currently recruiting (2013–; verified July 2015), Sponsor: James Murrough (Icahn School of Medicine at Mount Sinai). https://clinicaltrials.gov/ct2/show/NCT01882829?term=AVP-923&rank=16
- Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts (DDI), NCT02402595, Ongoing/Not recruiting (Feb. 2015–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02402595?term=AVP-923&rank=3
- Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease, NCT01832350, Ongoing/Not recruiting (2013–), Sponsor: St. Joseph's Hospital and Medical Center, Phoenix, (Collaborator: Avanir Pharm.). https://www.clinicaltrials.gov/ct/show/NCT01832350
- Clinical Trial Nuedexta in Subjects With ALS, NCT01806857, Ongoing/Not recruiting (2013–), Sponsor: Center for Neurologic Study, La Jolla, California. https://clinicaltrials.gov/ct2/show/NCT01806857?term=AVP-923&rank=13
- Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) (PRISM II), NCT01799941, Ongoing/Not recruiting (2013–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT01799941?term=AVP-923&rank=10
- Nuedexta for the Treatment of Adults With Autism (Nuedexta), NCT01630811, Ongoing/Not recruiting (2012–), Sponsor: Sutter Health. https://clinicaltrials.gov/ct2/show/NCT01630811?term=AVP-923&rank=9
- A Phase 1 Study Comparing AVP-786 With AVP-923, NCT02336347, Completed (Jan. 2015–), Sponsor: Avanir Pharm. https://www.clinicaltrials.gov/ct2/show/NCT02336347?term=AVP-786&rank=4
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers, NCT02174835, Completed (2014–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02174835?term=AVP-923&rank=17
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects, NCT02174822, Completed (2014–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT02174822?term=avanir&rank=13
- Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers, NCT01787747, Completed (2013–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT01787747?term=AVP-923&rank=18
- Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients (LID in PD), NCT01767129, Completed (2013–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT01767129?term=AVP-923&rank=2
- Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients, NCT01584440, Completed (2012–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT01584440?term=avanir&rank=3
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis (PRIME), NCT01324232, Completed (2011–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT01324232
- Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy, NCT00113620, Completed (2005–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT00113620?term=AVP-923&rank=19
- Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter), NCT00056524, Completed (2003–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT00056524?term=AVP-923&rank=8
- Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients, NCT00050232, Completed (2002–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT00050232?term=AVP-923&rank=12
- Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS, NCT00021697, Completed (2001–), Sponsor: Avanir Pharm. https://clinicaltrials.gov/ct2/show/NCT00021697?term=AVP-923&rank=6
Prevalence estimates place the number of people with PBA between 1.5 and 2 million in the United States alone, which would be less than 1% of the U.S. population even at the high end of the estimate. Some argue that the number is probably higher and that clinicians underdiagnose PBA. However, the prevalence estimate of 2 million is based on an online survey. Self-selected computer-savvy patients in at-risk groups evaluated their own symptoms and submitted their self-diagnoses. No doctor or clinic confirmed the data. Motivation to participate could have been influenced by the presence of symptoms, which would have skewed the results. The actual prevalence could very well be quite a bit lower than estimated.
The Expression of the Emotions in Man and Animals by Charles Darwin was published in 1872. In Chapter VI, "Special Expressions of Man: Suffering and Weeping", Darwin discusses cultural variations in the acceptability of weeping and the wide differences in individual responses to suffering. The chapter contains the following sentence:
We must not, however, lay too much stress on the copious shedding of tears by the insane, as being due to the lack of all restraint; for certain brain-diseases, as hemiplegia, brain-wasting, and senile decay, have a special tendency to induce weeping.
- Archiniegas DB, Topkoff J (2000). "The neuropsychiatry of pathologic affect: an approach to evaluation and treatment". Seminars in Clinical Neuropsychiatry. 5 (4): 290–306. doi:10.1053/scnp.2000.9554. PMID 11291026.
- Cummings J, Arciniegas D, Brooks B, Herndon R, Lauterbach E, Pioro E, Robinson R, Scharre D, Schiffer R, Weintraub D; Arciniegas; Brooks; Herndon; Lauterbach; Pioro; Robinson; Scharre; Schiffer; Weintraub (2006). "Defining and diagnosing involuntary emotional expression disorder". CNS Spectrums. 11 (6): 1–7. PMID 16816786.
- Dark FL, McGrath JJ, Ron MA; McGrath; Ron (1996). "Pathological laughing and crying". Australian and New Zealand Journal of Psychiatry. 30 (4): 472–479. doi:10.3109/00048679609065020. PMID 8887697.
- Parvizi J, Archiniegas DB, Bernardini GL, Hoffman MW, et al. (2006). "Diagnosis and management of pathological laughter and crying". Mayo Clinic Proceedings. 81 (11): 1482–1486. doi:10.4065/81.11.1482. PMID 17120404.
- Skirrow, Caroline; Asherson, Philip (2013). "Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder". Journal of Affective Disorders. 147 (1–3): 80–6. doi:10.1016/j.jad.2012.10.011. PMID 23218897.
- Latoo, Javed; Mistry, Minal; Dunne, Francis J (2013). "Often overlooked neuropsychiatric syndromes in Parkinson's disease". British Journal of Medical Practitioners. 6 (1). Retrieved 4 November 2014.
- Levitt, S. (2013). Treatment of Cerebral Palsy and Motor Delay. Wiley. ISBN 9781118699782. Retrieved 4 November 2014.
- Atchison, B.; Dirette, D.K. (2007). Conditions in Occupational Therapy: Effect on Occupational Performance. Lippincott Williams & Wilkins. p. 40. ISBN 9780781754873. Retrieved 4 November 2014.
- Devinsky, O; Vazquez, B (1993). "Behavioral changes associated with epilepsy". Neurological Clinics. 11 (1): 127–49. PMID 8441366. Retrieved 4 November 2014.
- "Medscape: Medscape Access". medscape.com. Retrieved 4 November 2014.
- Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA; Gresham; Bromberg; Kasarkis; Smith (1997). "A self report measure of affective lability". Journal of Neurology, Neurosurgery, and Psychiatry. 63 (1): 89–93. doi:10.1136/jnnp.63.1.89. PMC . PMID 9221973.
- Shaibani AT, Sabbagh MN, Doody R (1994). "Laughter and crying in neurologic disorders". Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 7: 243–250.
- Black DW (1982). "Pathological laughter. A review of the literature". Journal of Nervous and Mental Disease. 170 (2): 67–71. doi:10.1097/00005053-198202000-00001. PMID 7057172.
- Green RL (1998). "Regulation of affect". Seminars in Clinical Neuropsychiatry. 3 (3): 195–200. PMID 10085207.
- Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR; Anderson; Martin; Damasio; Damasio (2001). "Pathological laughter and crying: a link to the cerebellum". Brain. 124 (Pt 9): 1708–1719. doi:10.1093/brain/124.9.1708. PMID 11522574.
- McCullagh S, Moore M, Gawel M, Feinstein A (1999). "Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction". Journal of the Neurological Sciences. 169: 43–48. doi:10.1016/s0022-510x(99)00214-2.
- Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR; Parikh; Lipsey; Starkstein; Price (1993). "Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study". American Journal of Psychiatry. 150 (2): 286–293. doi:10.1176/ajp.150.2.286. PMID 8422080.
- Lopez, Oscar L.; Gonzalez, Maria P.; Becker, James T.; Reynolds, Charles F.; Sudilovsky, Abraham; DeKosky, Steven T. (1996). "Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia: exploration of underlying mechanisms". Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 9 (3): 154–161.
- Tremont Geogffery. "Neurbehavioral Functioning in Thyroid Disorders". Medicine and Health.http://med.brown.edu/neurology/articles/gt31803.pdf
- Greenamyre JT (1986). "The role of glutamate in neurotransmission and in neurologic disease". Archives of Neurology. 43 (10): 1058–1063. doi:10.1001/archneur.1986.00520100062016. PMID 2428340.
- Bittigau P, Ikonomidou C; Ikonomidou (1997). "Glutamate in neurologic diseases". Journal of Child Neurology. 12 (8): 461–485. doi:10.1177/088307389701200802. PMID 9430311.
- Mattson MP (2003). "Excitotoxic and excitoprotective mechanism: abundant targets for the prevention and treatment of neurodegenerative disorders". Neuromolecular Medicine. 3 (2): 65–94. doi:10.1385/NMM:3:2:65. PMID 12728191.
- House A, Dennis M, Molyneux A, Warlow C, Hawton K; Dennis; Molyneux; Warlow; Hawton (1989). "Emotionalism after stroke". BMJ. 298 (6679): 991–994. doi:10.1136/bmj.298.6679.991. PMC . PMID 2499390.
- Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K; Hornstein; Flax; Herbert; Schroeder (1992). "Fluoxetine improves emotional incontinence". Brain Injury. 6 (3): 267–270. doi:10.3109/02699059209029668. PMID 1581749.
- Feinstein A, Feinstein K, Gray T, O'Connor P; Feinstein; Gray; O'Connor (1997). "Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis". Archives of Neurology. 54 (9): 1116–1121. doi:10.1001/archneur.1997.00550210050012. PMID 9311355.
- Kim JS (2002). "Post-stroke emotional incontinence after small lenticulocapsular stroke: correlation with lesion location". Journal of Neurology. 249 (7): 805–810. doi:10.1007/s00415-002-0714-4. PMID 12140660.
- Harris Y, Gorelick PB, Cohen D, Dollear W, et al. (1994). "Psychiatric symptoms in dementia associated with stroke: a case-control analysis among predominantly African-American patients". Journal of the National Medical Association. 86 (9): 697–702. PMC . PMID 7966434.
- Ross ED, Stewart RS; Stewart (1987). "Pathological display of affect in patients with depression and right frontal brain damage. An alternative mechanism". Journal of Nervous and Mental Disease. 175 (3): 165–172. doi:10.1097/00005053-198703000-00007. PMID 3819712.
- Haupt (1996). "Emotional lability, intrusiveness, and catastrophic reactions". International Psychogeriatrics. 8 (Suppl 3): 409–414. doi:10.1017/S1041610297003736. PMID 9154598.
- Sloan RL, Brown KW, Pentland B; Brown; Pentland (1992). "Fluoxetine as a treatment for emotional lability after brain injury". Brain Injury. 6 (4): 315–319. doi:10.3109/02699059209034945. PMID 1638265.
- Surridge D (1969). "An investigation into some psychiatric aspects of multiple sclerosis". British Journal of Psychiatry. 115 (524): 749–764. doi:10.1192/bjp.115.524.749. PMID 5806869.
- Caroscio JT, Mulvihill MN, Sterling R, Abrams B; Mulvihill; Sterling; Abrams (1987). "Amyotrophic lateral sclerosis". Neurological Clinics. 5 (1): 1–8. PMID 3561382.
- Gallagher JP (1989). "Pathologic laughter and crying in ALS: a search for their origin". Acta Neurologica Scandinavica. 80 (2): 114–117. doi:10.1111/j.1600-0404.1989.tb03851.x. PMID 2816272.
- Wicks P Frost J; Frost (2008). "ALS patients request more information about cognitive symptoms". European Journal of Neurology. 15 (5): 497–500. doi:10.1111/j.1468-1331.2008.02107.x. PMID 18325023.
- Zeilig G, Drubach DA, Katz-Zeilig M, Karatinos J; Drubach; Katz-Zeilig; Karatinos (1996). "Pathological laughter and crying in patients with closed traumatic brain injury". Brain Injury. 10 (8): 591–597. doi:10.1080/026990596124160. PMID 8836516.
- http://www.biausa.org/_literature_77385/1-7-2011_PBA_Survey_Results[full citation needed]
- Fellus JL, Kantor D, Kaye RE (2012). "PRISM registry: A novel research tool to determine the prevalence of pseudobulbar affect". European Journal of Neurology. 19 (S1): 85–90. doi:10.1111/j.1468-1331.2012.03887.x.
- Burns, Alistair; Russell, Eve; Stratton-Powell, Hilary; Tyrell, Pippa; O'Neill, Paul; Baldwin, Robert (1999). "Sertraline in stroke-associated lability of mood". International Journal of Geriatric Psychiatry. 14 (8): 681–5. doi:10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.0.CO;2-Z. PMID 10489659.
- Brown, K. W.; Sloan, R. L.; Pentland, B. (1998). "Fluoxetine as a treatment for post-stroke emotionalism". Acta Psychiatrica Scandinavica. 98 (6): 455–8. doi:10.1111/j.1600-0447.1998.tb10119.x. PMID 9879787.
- Andersen, G; Vestergaard, K; Riis, J. O. (1993). "Citalopram for post-stroke pathological crying". The Lancet. 342 (8875): 837–9. doi:10.1016/0140-6736(93)92696-Q. PMID 8104273.
- Robinson, RG; Parikh, RM; Lipsey, JR; Starkstein, SE; Price, TR (1993). "Pathological laughing and crying following stroke: Validation of a measurement scale and a double-blind treatment study". American Journal of Psychiatry. 150 (2): 286–93. doi:10.1176/ajp.150.2.286. PMID 8422080.
- Schiffer, Randolph B.; Herndon, Robert M.; Rudick, Richard A. (1985). "Treatment of Pathologic Laughing and Weeping with Amitriptyline". The New England Journal of Medicine. 312 (23): 1480–2. doi:10.1056/NEJM198506063122303. PMID 3887172.
- "Dextromethorphan (DXM)". Cesar.umd.edu. Retrieved 2016-02-18.
- "Label: NUEDEXTA- dextromethorphan hydrobromide and quinidine sulfate capsule, gelatin coated". U.S. National Library of Medicine, DailyMed. 2015-01-30. Retrieved 2016-02-18.
- "Quinidine sulfate". PDRhealth™. 2016. Retrieved 2016-02-18.
- "Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference". PR Newswire. 2015-07-23. Retrieved 2016-02-18.
- "Nuedexta, FDA Approval History". Drugs.com. January 2015. Retrieved 2016-02-18.
- "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS (STAR)". ClinicalTrials.gov. June 2013. Retrieved 2016-02-19.
- Pioro, Erik P.; Brooks, Benjamin Rix; Cummings, Jeffrey; Schiffer, Randolph; Thisted, Ronald A.; Wynn, Daniel; Hepner, Adrian; Kaye, Randall (2010). "Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect". Annals of Neurology. 68 (5): 693–702. doi:10.1002/ana.22093. PMID 20839238.
- "Avanir Pharmaceuticals, Inc, COMPANY DESCRIPTION". Seeking Alpha. Retrieved 2016-02-18.
- Soble, Jonathan (December 2, 2014). "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". The New York Times. Retrieved 2016-02-18.
- "Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion". PR Newswire. December 2, 2014. Retrieved 2016-02-18.
- "Avanir rises on faster development for new drug; Avanir says FDA speeds up development of new version of Nuedexta, and stock jumps". AP. June 5, 2013. Retrieved 2016-02-19.
- "Product Pipeline, Partnered Drug Candidates". 2016. Retrieved 2016-02-19.
- "Avanir to Expedite AVP-786 Development". Zacks Equity Research. June 6, 2013. Retrieved 2016-02-19.
- "Company Overview of Concert Pharmaceuticals, Inc.". 2016. Retrieved 2016-02-19.
- Archiniegas DB, Lauterbach EC, Anderson KE, Chow TW, et al. (2005). "The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting". CNS Spectrums. 10 (5): 1–16. PMID 15962457.
- Brooks, Benjamin Rix; Crumpacker, David; Fellus, Jonathan; Kantor, Daniel; Kaye, Randall E (Aug 21, 2013). "PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions". PLOS ONE. Public Library of Science. 8 (8): e72232. doi:10.1371/journal.pone.0072232. PMC . PMID 23991068.
- p. 156 http://darwin-online.org.uk/content/frameset?pageseq=1&itemID=F1142&viewtype=text
- "Pseudobulbar affect and stroke" on the National Stroke Association website